Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna earned approval for mResvia, a respiratory syncytial virus vaccine, on May 31. Instead of soaring in response to the great news, Moderna stock fell.

Is Moderna Stock a Buy Now That It's a 2-Product Company?

Moderna announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for adults ages 60 and older. This will be the only RSV vaccine available in single-dose prefilled syringes and will be sold under the brand name mRESVIA.

Moderna secures a second FDA vaccine approval as Spikevax sales plummet

Moderna has brought in billions of dollars in earnings thanks to its coronavirus vaccine. But demand for that product has declined, and that has worried investors.

Moderna Investors Just Got Some Bullish News

Moderna, Inc. (NASDAQ:MRNA ) Bernstein's 40th Annual Strategic Decisions Conference May 31, 2024 10:00 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Courtney Breen - Bernstein Courtney Breen Hi, there, everyone. It's great to see you all on Friday of the conference.

Moderna, Inc. (MRNA) Bernstein's 40th Annual Strategic Decisions Conference (Transcript)

Moderna Inc.'s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved for a disease other than COVID-19.

Moderna wins second product approval with RSV vaccine

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK

The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

US FDA approves Moderna's RSV vaccine, its second marketed product

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna.

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

Ginkgo Bioworks Holdings

Rallybio Corp

Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut.

3 Sorry Biotech Stocks to Sell in May While You Still Can

Investors appear to be taking profits after Moderna stock soared last week. The big moves center around concerns about the H5N1 avian flu, also known as bird flu.

Why Moderna Stock Is Sinking This Week

BioNTech SE

Pfizer

A new human bird-flu case identified in a Michigan dairy worker is the first in the U.S. to involve acute respiratory symptoms, the Centers for Disease Control and Prevention said Thursday.

New U.S. bird-flu case is first with respiratory symptoms, CDC says

Moderna stock jumped early Thursday after confirming the U.S. government is nearing a deal to fund its pandemic bird flu vaccine.

Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine

Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.

Moderna's stock climbs on report that bird-flu vaccine funding is near

This iron condor trade on Moderna has the potential to return 28% if the stock price stays between 118.90 and 181.10.

Option Trade On Volatile Moderna Could Return 28% By Mid-July

Constellation Energy Corp

CrowdStrike

The Nasdaq hit a new record high again on Tuesday. It has investors wondering which Nasdaq stocks to sell to lock in profits before the upside runs its course.

3 Nasdaq Stocks to Dump as They Near Peak Performance

The U.S. government is closing in on a deal to fund a late-stage trial for an mRNA pandemic bird flu vaccine made by Moderna, the Financial Times reported Thursday, at a time when the country is battling an H5N1 outbreak in cattle and poultry farms.

U.S. Government Nears Deal To Fund Moderna mRNA Bird Flu Shot Trial, Report Says

The U.S. government is nearing an agreement to fund a late-stage trial of Moderna's mRNA pandemic bird flu vaccine, the Financial Times reported on Thursday, as an H5N1 outbreak spreads through egg farms and among cattle herds.

US nears deal to fund Moderna's bird flu vaccine trial, FT reports

Micron Technology

NVIDIA

QUALCOMM

The Nasdaq Composite Index topped the 17,000 level for the first time. We have highlighted five best-performing stocks of QQQ this year that led the way higher in the portfolio.

Nasdaq Tops 17K: 5 Best-Performing Stocks in ETF YTD

Prime Medicine Inc

Viking Therapeutics

Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero.

If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names

The drop comes as Moderna awaits important developments involving its experimental cancer treatment, a new respiratory vaccine, and a possible avian flu vaccine under development.

Moderna Shares Had a Bad Day. Here's Why.

Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Moderna's leading non-COVID candidate won't earn approval when the biotech hoped. However, the delay should be a relatively short one if we believe the word of regulators.

Should You Buy This Stock After a Regulatory Setback?

Gilead Sciences

Immunocore Holdings

The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

Novavax

H5N1 bird flu was detected this week in Michigan and Australia. It's the first detection in humans since March, when news of an outbreak in cattle emerged.

News for Moderna Stock (MRNA)